• Todd J Anderson, Jean Grégoire, Robert A Hegele, Patrick Couture, G B John Mancini, Ruth McPherson, Gordon A Francis, Paul Poirier, David C Lau, Steven Grover, Jacques Genest, André C Carpentier, Robert Dufour, Milan Gupta, Richard Ward, Lawrence A Leiter, Eva Lonn, Dominic S Ng, Glen J Pearson, Gillian M Yates, James A Stone, and Ehud Ur.
• Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada. todd.anderson@albertahealthservices.ca
• Can J Cardiol. 2013 Feb 1;29(2):151-67.

AbstractMany developments have occurred since the publication of the widely-used 2009 Canadian Cardiovascular Society (CCS) Dyslipidemia guidelines. Here, we present an updated version of the guidelines, incorporating new recommendations based on recent findings and harmonizing CCS guidelines with those from other Societies. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) system was used, per present standards of the CCS. The total cardiovascular disease Framingham Risk Score (FRS), modified for a family history of premature coronary disease, is recommended for risk assessment. Low-density lipoprotein cholesterol remains the primary target of therapy. However, non-high density lipoprotein cholesterol has been added to apolipoprotein B as an alternate target. There is an increased emphasis on treatment of higher risk patients, including those with chronic kidney disease and high risk hypertension. The primary panel has recommended a judicious use of secondary testing for subjects in whom the need for statin therapy is unclear. Expanded information on health behaviours is presented and is the backbone of risk reduction in all subjects. Finally, a systematic approach to statin intolerance is advocated to maximize appropriate use of lipid-lowering therapy. This document presents the recommendations and principal conclusions of this process. Along with associated Supplementary Material that can be accessed online, this document will be part of a program of knowledge translation. The goal is to increase the appropriate use of evidence-based cardiovascular disease event risk assessment in the management of dyslipidemia as a fundamental means of reducing global risk in the Canadian population.Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

17 keywords...

hide…